Moderna Stock Plunges 18% Despite Positive Cancer Vaccine Data

October 23, 2026 | TickerRoast Markets Analysis

Moderna shares suffered one of the sharpest one-day declines in the company’s history on October 22, 2026, even though the latest data on its personalized melanoma vaccine with Merck looked positive. The reaction highlights how much optimism had been built into a stock that had gained more than 500% since the start of the year, and why strong clinical results do not always translate into a higher share price.

What Happened

On Thursday, October 22, results from the Phase 3 INTerpath-001 trial of intismeran autogene, the individualized mRNA cancer vaccine Moderna is developing with Merck, appeared on a medical news website shortly after midday and were taken down soon afterward, according to 24/7 Wall St. More detailed results released later that day showed that the vaccine combined with Merck’s immunotherapy Keytruda reduced the risk of recurrence or death by 42% compared with Keytruda alone, Reuters reported.

The share price moved in the opposite direction. According to Reuters, Moderna was down more than 25% at one point during the session, on track for its steepest one-day percentage fall on record, and the selloff erased roughly $24 billion of market value. Based on Yahoo Finance data, the stock closed at $202.63, down 17.57% from the previous close of $245.81, after touching an intraday low of $180.80. Trading volume reached about 49.8 million shares, roughly 2.8 times the 20-day average.

The move spilled over into the sector only modestly. Reuters reported that Merck shares fell nearly 1%, while 24/7 Wall St. noted that BioNTech dipped about 2% intraday and Pfizer edged higher.

What the Trial Showed

INTerpath-001 is a randomized, double-blind Phase 3 study that enrolled 1,137 patients with high-risk, completely resected cutaneous melanoma (stage IIB to IV) who had not received prior systemic therapy. Patients were randomized 2:1 to intismeran plus Keytruda or Keytruda alone, according to the companies’ August announcement.

In August, Merck and Moderna said a prespecified interim analysis met the primary endpoint of recurrence-free survival and the key secondary endpoint of distant metastasis-free survival, with a safety profile consistent with earlier studies and no new safety signals. Detailed figures were not released at the time.

Measure (vs. Keytruda alone)	Result reported on Oct. 22	Source
Risk of recurrence or death	42% reduction	Reuters, via Yahoo Finance
Risk of distant metastasis or death	38% reduction	Reuters, via Yahoo Finance
Period covered	First two years after treatment	Reuters, via Yahoo Finance
Overall survival	Not yet mature; “favorable trend” per the companies	Reuters, via Yahoo Finance
Patients enrolled	1,137 (randomized 2:1)	Company announcement, Aug. 19, 2026

Analysts quoted by Reuters described the data favorably. UBS analyst Michael Yee called the recurrence-free survival results “solid data,” and TD Cowen said the 42% reduction was compelling and fell within the range medical experts consider exceptional. The vaccine remains investigational and has not been approved by any regulator.

Why the Stock Fell Despite Good Results

In our view, the decline reflects expectations rather than a disappointment in the data itself. Several factors appear to have combined.

A very large run-up. Based on Yahoo Finance data, Moderna had risen about 557% year to date and about 275% over the previous three months before the drop. Much of the positive scenario was arguably already reflected in the share price.
Sell-the-news dynamics. UBS’s Michael Yee and William Blair’s Myles Minter both described the reversal as a sell-the-news reaction, according to Reuters. When a widely anticipated catalyst arrives, some investors take profits regardless of the outcome.
Questions beyond melanoma. Minter questioned whether the vaccine will work as well in other cancer types, which Reuters noted could be needed to justify the company’s valuation.
Valuation skepticism already on record. On September 30, Citi analyst Geoff Meacham downgraded Moderna to Sell from Hold with an $80 price target, according to 24/7 Wall St., arguing that the share price increasingly assumed successful expansion into several additional tumor types.
The disorderly disclosure. The early appearance of results on a third-party website, before the companies’ planned release, added uncertainty to an already crowded trade.

Business and Valuation Context

Moderna’s 2026 rally was driven largely by investor enthusiasm for its oncology pipeline rather than by its established respiratory vaccine business. Intismeran is the most advanced program in that pipeline, which makes the melanoma data a central input for any assessment of the company’s long-term prospects.

The positive results strengthen the scientific case for individualized mRNA cancer vaccines, but they also narrow the debate. With efficacy in resected melanoma now supported by Phase 3 data, attention is likely to shift to questions that are harder to answer today: the scope and timing of potential regulatory filings, manufacturing capacity for a personalized product, pricing, the economics of the Merck partnership, and whether the approach can be replicated in other tumor types. Each of these factors could influence how investors value the program, and none has been resolved by this week’s data.

Technical Picture

The six-month chart shows the scale of the rally that preceded the drop. Based on Yahoo Finance data as of the October 22 close, Moderna traded just below its 20-day simple moving average of $210.43 but well above its 50-day average of $168.42 and its 200-day average of $81.34. The 14-day relative strength index (RSI) eased to about 51, a neutral reading, after the stock had set a 52-week high of $254.48 on October 21.

The heavy volume behind the decline indicates broad participation in the selling. Technical indicators describe past price behavior only and do not predict future moves, particularly for a stock exposed to binary clinical and regulatory events.

Key Risks

Data interpretation: the full dataset, including subgroup analyses and overall survival trends, may be received differently by clinicians and investors than the headline figures.
Regulatory risk: the companies have said they will engage with regulators, but the timing and outcome of any filing are uncertain.
Commercial execution: producing an individualized vaccine for each patient raises manufacturing, logistics and cost challenges that are not yet visible in trial results.
Pipeline concentration: a large share of investor expectations rests on one program and on its potential expansion into other cancers.
Volatility: after a rally of this size, the stock may remain highly sensitive to news flow, as the October 22 session demonstrated.

What Investors Will Watch Next

The detailed presentation of INTerpath-001 results scheduled for Saturday, October 24, at the European Society for Medical Oncology (ESMO) Congress in Madrid, as reported by Reuters.
Any updates on overall survival as the data mature.
Communication from Moderna and Merck on regulatory submissions and their expected timeline.
Progress of intismeran in trials in other tumor types.
Moderna’s next quarterly results and any update to its financial outlook.

These events may influence sentiment in either direction, and their outcomes cannot be known in advance.

Conclusion

Moderna’s October 22 decline is a reminder that in biotech, the direction of a stock after a clinical readout depends as much on what was already priced in as on the data itself. The INTerpath-001 results, as reported, support the potential of intismeran in high-risk melanoma. However, after a gain of more than 500% this year, investors appear to have shifted their focus from whether the vaccine works to how large, how fast and how broadly it can become a commercial product.

The ESMO presentation, the maturity of survival data and the regulatory path will provide more information in the coming months. Until then, the debate over Moderna’s valuation is likely to remain as intense as the stock’s recent moves.

Sources

Moderna sheds about $24 billion as cancer vaccine data triggers ‘sell-the-news’ retreat (Reuters) — Yahoo Finance / Reuters
Moderna Tumbles 25% After Apparent Early Leak of Melanoma Vaccine Data; BioNTech Dips, Pfizer Edges Higher — 24/7 Wall St.
Merck and Moderna’s Intismeran Plus KEYTRUDA Meets Phase 3 Melanoma Trial Endpoints — Pulse 2.0
Moderna Sinks 6% on Citi Downgrade; Merck and Pfizer Stay Flat — 24/7 Wall St.

Market data: Yahoo Finance, close of 2026-10-22.

Disclaimer: This article is for informational and educational purposes only. It provides general financial and business analysis and does not constitute investment advice, a personal recommendation, a recommendation to buy, sell or hold any security, or an offer to transact in any financial instrument. Information is based on publicly available sources as of October 23, 2026 and market data as of the 2026-10-22 close (Yahoo Finance). Past performance is not a reliable indicator of future results; forecasts are uncertain and actual results may differ materially. Investing in shares involves risk, including the loss of capital. The publisher does not guarantee the accuracy or completeness of the information and accepts no responsibility for investment decisions made on the basis of this article. Readers should consult official company disclosures, conduct their own research and, where appropriate, seek advice from a licensed financial adviser. Any relevant financial interests held by the author or publisher in the securities mentioned are disclosed where applicable. This article was prepared with the assistance of AI tools and is based on the sources listed above.

Get the daily market briefing

The stories that move markets, in your inbox every trading day at 9 a.m. ET. Free, unsubscribe anytime.

Why Did Moderna Stock Plunge 18% on Positive Cancer Vaccine Data? Inside the Sell-the-News Reversal